Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teriflunomide versus placebo in pediatric relapsing multiple sclerosis
NL-OMON47604Phase 3Completed
- Sponsor
- Sanofi
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in multiple sclerosis (MS) comparing Teriflunomide with Placebo (2 arms). Primary endpoint: Time to first clinical relapse after randomization. Started Apr 2017; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON47604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47604.